Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARCT OTCMKTS:BSEM NASDAQ:ETON NASDAQ:KOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.99+0.3%$15.22$8.04▼$25.88$487.15M2.39639,028 shs439,555 shsBSEMBioStem Technologies$5.83-0.5%$9.42$5.02▼$28.26$98.14M-0.32102,454 shs81,146 shsETONEton Pharmaceuticals$17.42-2.4%$15.93$4.73▼$21.48$478.69M1.1243,222 shs149,481 shsKODKodiak Sciences$9.73-3.3%$7.65$1.92▼$11.60$531.39M2.45666,675 shs303,438 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.56%+7.43%+50.63%+44.21%-5.58%BSEMBioStem Technologies-5.18%-12.14%-43.38%-58.05%-38.83%ETONEton Pharmaceuticals+0.39%+3.84%+4.14%+18.29%+282.23%KODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARCTArcturus Therapeutics$17.99+0.3%$15.22$8.04▼$25.88$487.15M2.39639,028 shs439,555 shsBSEMBioStem Technologies$5.83-0.5%$9.42$5.02▼$28.26$98.14M-0.32102,454 shs81,146 shsETONEton Pharmaceuticals$17.42-2.4%$15.93$4.73▼$21.48$478.69M1.1243,222 shs149,481 shsKODKodiak Sciences$9.73-3.3%$7.65$1.92▼$11.60$531.39M2.45666,675 shs303,438 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARCTArcturus Therapeutics+0.56%+7.43%+50.63%+44.21%-5.58%BSEMBioStem Technologies-5.18%-12.14%-43.38%-58.05%-38.83%ETONEton Pharmaceuticals+0.39%+3.84%+4.14%+18.29%+282.23%KODKodiak Sciences+2.76%+16.71%+27.34%+149.63%+322.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARCTArcturus Therapeutics 3.00Buy$50.57181.11% UpsideBSEMBioStem Technologies 0.00N/AN/AN/AETONEton Pharmaceuticals 3.00Buy$29.6770.30% UpsideKODKodiak Sciences 2.00Hold$11.7520.76% UpsideCurrent Analyst Ratings BreakdownLatest BSEM, ETON, ARCT, and KOD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ARCTArcturus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.008/22/2025ARCTArcturus TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$63.00 ➝ $54.008/18/2025KODKodiak SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.00 ➝ $5.008/14/2025KODKodiak SciencesBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderweight$4.00 ➝ $7.008/14/2025KODKodiak SciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeUnderweight ➝ Neutral$15.008/12/2025ARCTArcturus TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$47.00 ➝ $49.008/12/2025ARCTArcturus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$45.00 ➝ $42.007/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform7/2/2025ARCTArcturus TherapeuticsScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Outperform$32.00 ➝ $35.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARCTArcturus Therapeutics$152.31M3.21N/AN/A$8.90 per share2.02BSEMBioStem Technologies$301.83M0.32N/AN/AN/A∞ETONEton Pharmaceuticals$39.01M11.98N/AN/A$0.94 per share18.53KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARCTArcturus Therapeutics-$80.94M-$2.23N/AN/AN/A-49.26%-24.87%-17.75%11/6/2025 (Estimated)BSEMBioStem TechnologiesN/A$1.145.112.55N/AN/AN/AN/A11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A34.84N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)KODKodiak Sciences-$176.21M-$3.80N/AN/AN/AN/A-155.27%-63.29%11/13/2025 (Estimated)Latest BSEM, ETON, ARCT, and KOD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025KODKodiak Sciences-$1.01-$1.03-$0.02-$1.03N/AN/A8/11/2025Q2 2025ARCTArcturus Therapeutics-$1.11-$0.34+$0.77-$0.34$17.64 million$28.30 million8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARCTArcturus TherapeuticsN/AN/AN/AN/AN/ABSEMBioStem TechnologiesN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARCTArcturus TherapeuticsN/A5.905.90BSEMBioStem TechnologiesN/AN/AN/AETONEton Pharmaceuticals1.141.771.16KODKodiak SciencesN/A3.483.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARCTArcturus Therapeutics94.54%BSEMBioStem TechnologiesN/AETONEton Pharmaceuticals27.86%KODKodiak Sciences89.06%Insider OwnershipCompanyInsider OwnershipARCTArcturus Therapeutics16.60%BSEMBioStem TechnologiesN/AETONEton Pharmaceuticals16.03%KODKodiak Sciences45.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARCTArcturus Therapeutics18027.16 million22.65 millionOptionableBSEMBioStem TechnologiesN/A16.75 millionN/AN/AETONEton Pharmaceuticals2026.82 million22.52 millionOptionableKODKodiak Sciences9052.82 million28.58 millionOptionableBSEM, ETON, ARCT, and KOD HeadlinesRecent News About These CompaniesAdage Capital Partners GP L.L.C. Buys 186,180 Shares of Kodiak Sciences Inc. $KODSeptember 9 at 4:41 AM | marketbeat.comKodiak Sciences Inc. $KOD Shares Sold by Invesco Ltd.September 9 at 3:08 AM | marketbeat.comBrokers Offer Predictions for Kodiak Sciences Q3 EarningsSeptember 7 at 6:50 AM | marketbeat.comNuveen LLC Buys New Shares in Kodiak Sciences Inc. $KODSeptember 7 at 3:14 AM | marketbeat.comAnalysts Set Expectations for Kodiak Sciences Q3 EarningsSeptember 7 at 2:29 AM | americanbankingnews.comKodiak Sciences Inc. $KOD Shares Purchased by Nantahala Capital Management LLCSeptember 3, 2025 | marketbeat.comKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI)September 2, 2025 | prnewswire.comJim Cramer on Kodiak Sciences: “That’s a Pure Spec Stock”August 29, 2025 | insidermonkey.comHarbour BioMed Reports 2025 Interim ResultsAugust 27, 2025 | prnewswire.comCramer's Lightning Round: Oklo is a buyAugust 27, 2025 | msn.comICONIQ Capital LLC Purchases 249,699 Shares of Kodiak Sciences Inc. $KODAugust 26, 2025 | marketbeat.comKodiak Sciences: Odds May Be Narrowing For Longer Lasting Eye Disease Med ApprovalAugust 22, 2025 | seekingalpha.comQ3 EPS Estimates for Kodiak Sciences Raised by HC WainwrightAugust 22, 2025 | marketbeat.comKodiak Sciences Inc.'s (NASDAQ:KOD) high institutional ownership speaks for itself as stock continues to impress, up 11% over last weekAugust 20, 2025 | finance.yahoo.comKodiak Sciences (NASDAQ:KOD) Trading Down 6% - Here's What HappenedAugust 20, 2025 | marketbeat.comHC Wainwright Boosts Kodiak Sciences (NASDAQ:KOD) Price Target to $5.00August 20, 2025 | marketbeat.comKodiak Sciences to Present at American Chemical Society Fall 2025August 19, 2025 | prnewswire.comKodiak Sciences (NASDAQ:KOD) Shares Up 8.4% - Here's WhyAugust 17, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Shares Gap Up - Time to Buy?August 16, 2025 | marketbeat.comKodiak Sciences (NASDAQ:KOD) Rating Increased to Neutral at JPMorgan Chase & Co.August 16, 2025 | marketbeat.comXTX Topco Ltd Acquires New Stake in Kodiak Sciences Inc. (NASDAQ:KOD)August 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBSEM, ETON, ARCT, and KOD Company DescriptionsArcturus Therapeutics NASDAQ:ARCT$17.99 +0.05 (+0.28%) Closing price 04:00 PM EasternExtended Trading$17.73 -0.26 (-1.45%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.BioStem Technologies OTCMKTS:BSEM$5.83 -0.03 (-0.51%) As of 03:51 PM EasternBioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.Eton Pharmaceuticals NASDAQ:ETON$17.42 -0.43 (-2.41%) Closing price 04:00 PM EasternExtended Trading$17.42 0.00 (0.00%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Kodiak Sciences NASDAQ:KOD$9.73 -0.33 (-3.28%) Closing price 04:00 PM EasternExtended Trading$9.86 +0.13 (+1.28%) As of 06:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
